Novel agents versus chemotherapy as frontline treatment of CLL

Abstract

Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that are well tolerated and highly efficacious. The role of novel agents in the first-line setting is now being investigated in head-to-head clinical trials. In this discussion paper, we consider the role of novel agents in the up-front setting, using three case studies of treatment-naive patients to highlight how choice of therapy may be individualized depending on the characteristics of the patient and the disease, as well as patient preferences.

Keywords:

• Ibrutinib
• idelalisib
• venetoclax
• obinutuzmab

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http:10.1080/10428194.2017.1280606.